Prevalence of statin intolerance: a meta-analysis

I Bytyci, PE Penson, DP Mikhailidis… - European heart …, 2022 - academic.oup.com
Aims Statin intolerance (SI) represents a significant public health problem for which precise
estimates of prevalence are needed. Statin intolerance remains an important clinical …

A systematic review and meta‐analysis on the therapeutic equivalence of statins

TC Weng, YHK Yang, SJ Lin… - Journal of clinical …, 2010 - Wiley Online Library
Background: Statins are the most commonly prescribed agents for hypercholesterolemia
because of their efficacy and tolerability. As the number of patients in need of statin therapy …

Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs

Q Wang, Y Cao, L Shen, T Xiao, R Cao, S Wei… - Science …, 2022 - science.org
Cholesterol, an essential molecule for cell structure, function, and viability, plays crucial
roles in the development, progression, and survival of cancer cells. Earlier studies have …

High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions

P Barter, J Kastelein, A Nunn, R Hobbs, FFE Board - Atherosclerosis, 2003 - Elsevier
The concentration of high density lipoprotein-cholesterol (HDL-C) has been found
consistently to be a powerful negative predictor of premature coronary heart disease (CHD) …

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol …

J Sasaki, Y Ikeda, T Kuribayashi, K Kajiwara, S Biro… - Clinical …, 2008 - Elsevier
Background: Statin therapy has been found to produce substantial reductions in low-density
lipoprotein cholesterol (LDL-C) levels, resulting in a reduced risk for cardiovascular events …

Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions

S Yamashita, K Tsubakio-Yamamoto… - … of atherosclerosis and …, 2010 - jstage.jst.go.jp
HDL is a lipoprotein that plays a central role in reverse cholesterol transport (RCT). Hypo-
HDL-cholesterolemia has long been recognized as a strong and independent risk factor for …

[PDF][PDF] Drug class review HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin

MEB Smith, NJ Lee, E Haney, S Carson, M Helfand - Update, 2009 - ohsu.edu
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination
Products Containing a Statin Page 1 Drug Class Review HMG-CoA Reductase Inhibitors (Statins) …

Atorvastatin for lowering lipids

SP Adams, M Tsang, JM Wright - Cochrane Database of …, 2015 - cochranelibrary.com
Background This represents the first update of this review, which was published in 2012.
Atorvastatin is one of the most widely prescribed drugs and the most widely prescribed statin …

A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin

SL Rogers, DJ Magliano, DB Levison, K Webb… - Clinical …, 2007 - Elsevier
BACKGROUND:: The available statins exhibit differences in the potency with which they
alter serum lipid levels. OBJECTIVE:: Meta-analyses were conducted to assess the relative …

Deciphering Cholesterol's Role in PD-L2 Stability: A Distinct Regulatory Mechanism From PD-L1

Y Zhang, T Xiao, M Wen, L Shen, L Du, S Wei… - Journal of Molecular …, 2024 - Elsevier
Programmed cell death 1 ligand 2 (PD-L2), a member of the B7 immune checkpoint protein
family, emerges as a crucial player in immune modulation. Despite its functional overlap with …